SG Americas Securities LLC Has $233,000 Stock Holdings in TG Therapeutics, Inc. (NASDAQ:TGTX)

SG Americas Securities LLC trimmed its holdings in TG Therapeutics, Inc. (NASDAQ:TGTX - Free Report) by 67.3% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 7,730 shares of the biopharmaceutical company's stock after selling 15,884 shares during the period. SG Americas Securities LLC's holdings in TG Therapeutics were worth $233,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors also recently made changes to their positions in TGTX. State Street Corp boosted its position in TG Therapeutics by 35.8% during the third quarter. State Street Corp now owns 9,094,158 shares of the biopharmaceutical company's stock worth $212,712,000 after purchasing an additional 2,398,015 shares during the period. Principal Financial Group Inc. lifted its stake in shares of TG Therapeutics by 1,549.4% during the 3rd quarter. Principal Financial Group Inc. now owns 772,188 shares of the biopharmaceutical company's stock worth $18,061,000 after buying an additional 725,371 shares during the last quarter. Public Sector Pension Investment Board bought a new stake in shares of TG Therapeutics during the 3rd quarter worth about $6,619,000. JPMorgan Chase & Co. grew its stake in TG Therapeutics by 60.0% in the 3rd quarter. JPMorgan Chase & Co. now owns 720,798 shares of the biopharmaceutical company's stock valued at $16,859,000 after buying an additional 270,286 shares during the last quarter. Finally, PFM Health Sciences LP bought a new position in TG Therapeutics in the 3rd quarter valued at about $5,459,000. 58.58% of the stock is currently owned by institutional investors.

Insider Buying and Selling

In other TG Therapeutics news, CFO Sean A. Power sold 10,021 shares of the business's stock in a transaction that occurred on Monday, January 6th. The shares were sold at an average price of $28.53, for a total transaction of $285,899.13. Following the completion of the transaction, the chief financial officer now directly owns 660,611 shares in the company, valued at $18,847,231.83. The trade was a 1.49 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. 10.50% of the stock is currently owned by company insiders.

TG Therapeutics Price Performance

TGTX traded down $0.84 on Monday, hitting $32.25. 1,488,998 shares of the stock were exchanged, compared to its average volume of 2,408,084. The firm has a market capitalization of $5.02 billion, a price-to-earnings ratio of -322.47 and a beta of 2.26. The company has a debt-to-equity ratio of 1.27, a current ratio of 4.59 and a quick ratio of 3.91. TG Therapeutics, Inc. has a 12 month low of $12.84 and a 12 month high of $36.84. The business has a 50-day moving average of $31.38 and a two-hundred day moving average of $27.11.

Analysts Set New Price Targets

A number of brokerages have recently issued reports on TGTX. StockNews.com cut TG Therapeutics from a "hold" rating to a "sell" rating in a report on Friday, January 31st. TD Cowen started coverage on TG Therapeutics in a research report on Tuesday, October 29th. They set a "buy" rating and a $50.00 price objective on the stock. JPMorgan Chase & Co. boosted their target price on shares of TG Therapeutics from $30.00 to $43.00 and gave the company an "overweight" rating in a research report on Monday, November 25th. HC Wainwright restated a "buy" rating and issued a $55.00 price target on shares of TG Therapeutics in a research note on Wednesday, January 15th. Finally, The Goldman Sachs Group increased their target price on shares of TG Therapeutics from $20.00 to $22.00 and gave the stock a "neutral" rating in a research report on Tuesday, November 5th. One investment analyst has rated the stock with a sell rating, one has issued a hold rating and five have given a buy rating to the stock. According to data from MarketBeat, TG Therapeutics has a consensus rating of "Moderate Buy" and an average target price of $40.67.

TG Therapeutics Company Profile

TG Therapeutics, Inc, a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults.